Analysts think SONN stock price could increase by 1269%
Dec 27, 2024, 12:25 PM
21.48%
What does SONN do
Sonnet BioTherapeutics Holdings, a clinical stage biotech based in Princeton, New Jersey, specializes in biologic medicines and has developed the FHAB technology for improved drug delivery in cancer treatment. Its lead assets include SON-1010 for solid tumors and SON-080 for chemotherapy-induced peripheral neuropathy.
3 analysts think SONN stock price will increase by 1269.13%. The current median analyst target is $20.40 compared to a current stock price of $1.49. The lowest analysts target is $20.20 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.